Clovis Oncology, Inc. (CLVS) Rating Reiterated by Oppenheimer Holdings, Inc.
Clovis Oncology, Inc. (NASDAQ:CLVS)‘s stock had its “hold” rating reissued by equities researchers at Oppenheimer Holdings, Inc. in a note issued to investors on Tuesday.
Other analysts have also issued reports about the company. Cann began coverage on Clovis Oncology in a research note on Thursday, June 22nd. They issued a “market perform” rating on the stock. Evercore ISI began coverage on Clovis Oncology in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 price target on the stock. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 18th. Leerink Swann lowered their price target on Clovis Oncology to $107.00 and set an “outperform” rating on the stock in a research note on Friday, August 18th. Finally, BidaskClub raised Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $87.09.
Shares of Clovis Oncology (NASDAQ CLVS) opened at 82.78 on Tuesday. Clovis Oncology has a one year low of $25.81 and a one year high of $99.45. The stock’s market capitalization is $4.05 billion. The stock’s 50 day moving average price is $76.15 and its 200 day moving average price is $70.77.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.27) by ($0.02). The firm had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $13.07 million. Clovis Oncology’s revenue was down 32.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.07) earnings per share. Equities research analysts predict that Clovis Oncology will post ($7.55) EPS for the current fiscal year.
In other Clovis Oncology news, Director James C. Blair sold 18,450 shares of Clovis Oncology stock in a transaction on Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Following the sale, the director now owns 2,185 shares in the company, valued at $171,762.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Friday, September 15th. The shares were sold at an average price of $69.50, for a total value of $208,500.00. Following the completion of the sale, the insider now owns 191,583 shares in the company, valued at approximately $13,315,018.50. The disclosure for this sale can be found here. Insiders sold 27,450 shares of company stock worth $2,143,685 in the last 90 days. Company insiders own 12.50% of the company’s stock.
A number of large investors have recently bought and sold shares of CLVS. Phocas Financial Corp. purchased a new stake in Clovis Oncology in the second quarter valued at $112,000. Advisors Asset Management Inc. raised its position in Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the period. PNC Financial Services Group Inc. raised its position in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 100 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in Clovis Oncology in the first quarter valued at $195,000. Finally, Teacher Retirement System of Texas purchased a new stake in Clovis Oncology in the first quarter valued at $204,000. Institutional investors own 99.03% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.